CANF - Can-Fite BioPharma Ltd.

QQQ $ 429.07 $ 5.38 (1.28 %)

DIA $ 382.31 $ 3.34 (0.88 %)

SPY $ 505.01 $ 4.68 (0.94 %)

TLT $ 88.87 $ 0.38 (0.43 %)

GLD $ 213.12 $ -0.66 (-0.31 %)

Previous Close

$ 2.03

Open

$ 2.08

Bid

$ 2.03 x 100

Ask

$ 0.00 x 0

Day's Range

$ 2.08 - $ 2.08

52 Week Range

$ 1.81 - $ 3.33

Volume

10,925

Average Volume

Market Cap

2.76B

Beta (5Y Monthly)

$ 0.69

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type	Report Link
No Data found

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

12-health-care-stocks-moving-in-thursdays-pre-market-session

12 Health Care Stocks Moving In Thursday's...
04/25/2024 12:06:47

Can-Fite Biopharma Announced It Published ...
04/25/2024 11:28:46

The Patient Participated In The Phase Ii Liver Cancer Study And Has Been Treated With Namodenoson For >7 Years Under Compass...

Can-Fite's Namodenoson Featured in Biomedi...
04/15/2024 11:06:38

Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule dr...

Can-Fite BioPharma Submits FDA with an IND...
04/03/2024 11:03:06

Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE:CANF), a biotechnology company advancing a pipeline of proprietary small molecule dru...

Can Fite Biofarma: Q4 Earnings Insights
03/28/2024 11:50:05

Can Fite Biofarma FY GAAP EPS $(0.01), Sam...
03/28/2024 11:23:54

Can Fite Biofarma (AMEX:CANF) reported quarterly losses of $(0.01) per share. This is unchanged from the same period last year....

Can-Fite BioPharma Announced Notice Of All...
02/28/2024 12:12:11

Can-Fite Expands the Out-Licensing Deal wi...
01/30/2024 12:03:19

Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE:CANF), a biotechnology company advancing a pipeline of proprietary small molecule dru...

Can-Fite's Latest Innovation: Namodenoson ...
12/20/2023 12:07:16

Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule dr...

Can-Fite Receives Positive Response From F...
12/18/2023 12:05:11

The plan has been submitted to allow enrollment of children with psoriasis to Can-Fite's upcoming Phase 3 pivotal clinical ...

Can-Fite Biopharma Has Completed The Desig...
12/04/2023 12:09:58

Recap: Can Fite Biofarma Q3 Earnings
11/30/2023 13:10:10

Can Fite Biofarma 9M Sales $588.00K Down F...
11/30/2023 12:16:14

Can Fite Biofarma (AMEX:CANF) reported $588.00 thousand in sales this quarter. This is a 4.08 percent decrease over sales of $6...

Can-Fite Biopharma Ltd Shares Resume Trade
11/21/2023 19:19:58

Can-Fite Announces Exercise Of Warrants Fo...
11/21/2023 18:55:51

Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule dr...

Can-Fite Biopharma Shares Halted, News Pen...
11/21/2023 18:35:08

why-is-liver-cancer-focused-can-fite-biopharma-stock-trading-higher-today

Why Is Liver Cancer Focused Can-Fite BioPh...
11/21/2023 17:04:15

Can-Fite BioPharma Ltd (NYSE: CANF) announced that a patient who participated in the Phase 2 Liver Cancer Study and was treated...

Can-Fite Says A Patient Who Participated I...
11/21/2023 12:06:41

Can-Fite has received agreement from both the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) on a ...

Can-Fite to Harness Artificial Intelligenc...
10/26/2023 11:09:34

Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule dr...

matson-to-rally-around-36-here-are-10-top-analyst-forecasts-for-tuesday

Matson To Rally Around 36%? Here Are 10 To...
10/24/2023 13:44:40

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including...